The most common adverse events were headache, diarrhea and weight gain. Despite the appearance of a greater occurrence of transient headaches, data suggest a preferred advantage of<unk>  over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.
Acalabrutinib
Zanubrutinib
Tucatinib
Ponatinib
Imatinib
Afatinib
Neratinib
Selpercatinib